Diabetic Ulcer Treatment Market Research Report: Information By Treatment (Wound Care Dressings, Wound Care Devices and Active Therapies), By Type (Foot Ulcer and Mouth Ulcer), By End-User (Hospitals and Clinics, Ambulatory Surgical Centers, and Academic and Research Organization) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Diabetic Ulcer Treatment Market Overview

Diabetic Ulcer Treatment Market Size was valued at USD 3.9 Billion in 2022. The diabetic ulcer treatment market industry is projected to grow from USD 4.23 Billion in 2023 to USD 8.12 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.5% during the forecast period (2023 - 2032). The primary market drivers influencing market expansion over the anticipated period are the rising prevalence of diabetes and the use of wound care products to avoid diabetic ulcers. Additionally, it is anticipated that the growing demand for urgent diabetic ulcer treatment would be satisfied by the expanded number of businesses engaged in the development of cutting-edge products for the treatment of diabetic ulcers.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Diabetes foot ulcers are a common complication that can have serious consequences if not adequately managed and treated. Peripheral neuropathy, peripheral arterial disease, and the delayed wound healing brought on by diabetes are only a few of the causes of their occurrence. Diabetes-related foot ulcers typically enlarge in the soles of the feet and, if ignored, can cause infection, tissue damage, and, in severe cases, amputation. To enhance wound healing, ward off infection, and lower the likelihood of complications, diabetic foot ulcer therapy is undertaken. Obesity, long-term diabetes, peripheral artery disease, inadequate glycemic management, underlying neuropathy, or inadequate foot care are anticipated to raise the likelihood of diabetic foot ulcers (DFU), which will eventually reduce mobility and cause other complications. Despite the widespread use of telehealth and telemedicine, diabetic foot ulcers need individualized care. Due to increased demand for DFU monitoring products, manufacturers increased their supply.

The ubiquity of marketing and rising consumer awareness of available treatments drive the market's growth. The public's knowledge of the fatal effects of untreated diabetic ulcers has increased substantially, resulting in a significant surge in demand for safe and incredibly effective wound-healing treatments. The players in the market for the treatment of diabetic ulcers are continuously investing resources in developing novel medicines that use innovative technologies. The dramatic increase in leg amputations has been a primary driving force behind the search for new treatments. Increases in the prevalence of diabetes, the population of people over 65, and technical improvements in wound care management goods are the main drivers propelling the market growth for treating diabetic foot ulcers. A key factor driving the market is the increased prevalence of diabetes worldwide. The need for efficient options for treating diabetic foot ulcers is rising along with the prevalence of diabetes.

According to Indian researchers, esmolol hydrochloride gel (Galnobax, NovaLead) applied twice daily appears to considerably improve the closure of diabetic foot ulcers, especially in individuals who have risk factors for poor wound healing. The US Food and Drug Administration has approved the short-acting beta-adrenergic receptor blocker esmolol for use in treating supraventricular tachycardia and other heart conditions.

Diabetic Ulcer Treatment Market Trends

• Rising cases of diabetes patients is driving the market growth

Due to the growing number of diabetes patients, the market CAGR for treating diabetic ulcers is predicted to grow in the next years. High blood sugar levels brought on by the metabolic illness diabetes cause substantial long-term damage to the heart, blood vessels, eyes, kidneys, and nerves. The major factor in developing foot ulcers is diabetes, which has boosted demand for diabetic ulcer treatment. For instance, the Centers for Disease Control and Prevention, a US-based national public health organization, estimates that in 2022, 37.3 million Americans—or 11.3% of the country's population—will have diabetes. Additionally, the International Diabetes Federation, a leading diabetes community with headquarters in Belgium, estimates that 537 million adults worldwide will have diabetes by the end of 2021, with 3 out of 4 of these adults living in low- and middle-income nations. As a result, the market for diabetic foot therapy is expanding as more people are being diagnosed with diabetes.

Growing consumer awareness of treatment options and the prevalence of marketing are both fueling the market's expansion. The demand for safe and extremely effective wound healing treatments is rising significantly as a result of a major increase in public awareness of the devastating implications of untreated diabetic ulcers. The diabetic ulcers treatment market's participants are constantly devoting resources to the creation of novel therapies that make use of cutting-edge technologies. A major factor in pushing the quest for novel treatments is the sharp increase in the number of leg amputations caused by diabetic ulcers.

In the diabetic ulcer treatment market, technological development is a major trend. Major industry companies are putting their attention on cutting-edge technologies as cloud-based Al technology for the diagnosis of diabetic ulcers. For instance, in October 2021, Manchester Metropolitan University, a research university technology company based in the UK, teamed up with Oracle Corporation, a multinational computer technology and database management company based in the US, to introduce FootSnap Al, a healthcare technology for diabetic foot issues. FootSnap Al is a mobile application that employs deep learning algorithms to precisely identify ulcers on photos of a patient's feet with high sensitivity (0.934) and specificity (0.911) in recognizing images. Thus, driving the diabetic ulcer treatment market revenue.

Diabetic Ulcer Treatment Market Segment Insights

Diabetic Ulcer Treatment Treatment Insights

The diabetic ulcer treatment market segmentation, based on treatment includes Wound Care Dressings, Wound Care Devices and Active Therapies. The wound care dressings segment dominated the market. The key drivers influencing this market segment are the increased emphasis that market participants are placing on R&D, the growth in the number of technologically advanced product launches, the increased awareness of these products in emerging markets, and the sharp increase in per capita healthcare spending. Additionally, by collecting excess exudate from the wound or providing moisture to dry wounds, wound dressings like hydrocolloid or hydrogel dressings assist maintain an appropriate moisture balance in the wound, fostering an environment that is conducive to healing.

Diabetic Ulcer Treatment Type Insights

The diabetic ulcer treatment market segmentation, based on type, includes Foot Ulcer and Mouth Ulcer. The foot ulcer category generated the most income. Diabetes patients have a high incidence of diabetic ulcers, which promotes segmental development. For instance, the frequency of diabetic ulcers worldwide is over 630 per 100,000 diabetic people, according to the Diabetic foot epidemiology and demographics 2021. Similar to this, 12% of persons with diabetes experience diabetic ulcers at some point in their lives, according to the CDC. Over the course of the analysis period, the business growth will be aided by the high incidence of diabetic ulcers.

Figure 1: Diabetic Ulcer Treatment Market, by Type, 2022 & 2032 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Diabetic Ulcer Treatment Type Insights

The diabetic ulcer treatment market segmentation, based on type, includes Hospitals and Clinics, Ambulatory Surgical Centers, and Academic and Research Organization. The hospitals and clinics category generated the most income. This is a result of hospitals using diabetic ulcer treatment alternatives more frequently, having the necessary competent staff on hand, and more patients choosing hospitals because of supportive policies. Additionally, patients are drawn to hospitals by favorable reimbursement scenarios, a multidisciplinary approach, and the convenience of having a variety of treatments or operations under one roof in a hospital setting, which supports the sector's growth.

Diabetic Ulcer Treatment Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American diabetic ulcer treatment market area will dominate this market. The rising incidence of diabetes in the area is responsible for the market's flourishing expansion. In North America, the prevalence of diabetes has been progressively increasing as a result of sedentary lifestyles, poor eating patterns, and an aging population. The management and results of diabetic ulcers have also been improved by developments in medical technology and therapy alternatives. Similar to how early detection and treatment of diabetic ulcers are aided by awareness campaigns, educational initiatives, and greater understanding of diabetes management among healthcare professionals and patients, same factors are driving regional diabetic ulcers treatment market statistics.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: DIABETIC ULCER TREATMENT MARKET SHARE BY REGION 2022 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe diabetic ulcer treatment market accounts for the second-largest market share due to the growing number of diabetic ulcers among adults and the elderly population. Along with this, it is anticipated that in the upcoming years, the market will experience development due to a rise in the adoption of technologically advanced treatment alternatives in nations like Germany, France, and the United Kingdom. Further, the German diabetic ulcer treatment market held the largest market share, and the UK diabetic ulcer treatment market was the fastest growing market in the European region

The Asia-Pacific Diabetic ulcer treatment Market is expected to grow at the fastest CAGR from 2023 to 2032. The regional market is expanding as a result of increased diabetes prevalence and a sizable elderly population in China and India. Additionally, favorable legislation and rising use in developed nations like Australia and Japan might also be credited. Moreover, China’s diabetic ulcer treatment market held the largest market share, and the Indian diabetic ulcer treatment market was the fastest growing market in the Asia-Pacific region.

Diabetic Ulcer Treatment Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the diabetic ulcer treatment market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, diabetic ulcer treatment industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the diabetic ulcer treatment industry to benefit clients and increase the market sector. In recent years, the diabetic ulcer treatment industry has offered some of the most significant advantages to market. Major players in the diabetic ulcer treatment market attempting to increase market demand by investing in research and development operations include Smith & Nephew PLC (UK), Integra LifeSciences Corporation (US), SANUWAVE Health, Cardinal Health (US), 3M (US), Braun Melsungen AG (Germany) and ACELITY L.P. INC. (US).

Acelity is a leader in advanced wound care, providing patients in more than 90 countries with novel solutions from the hospital to the home. Its goal is to transform medical practice by offering treatments that hasten recovery, generate revenue, and enhance patient quality of life. They are the undisputed market leader in collagen dressings and the leader in negative pressure wound therapy. Acelity is based in San Antonio, Texas, and has close to 5,000 staff members worldwide.

Cardinal Health, Inc. is a worldwide American health care services firm that generates the 14th biggest amount of revenue in the US. The corporation, which has its headquarters in Dublin, Ohio, distributes pharmaceuticals and medical supplies to more than 100,000 locations. Additionally, the business produces surgical and medical goods such gloves, scrubs, and fluid management items. Furthermore, it runs one of the biggest radio-pharmacies networks in the country. 

Now, Queen's University Belfast researchers are employing 3D printing technology to cure patients. During their research, they developed 3D-printed bandages known as scaffolds, a breakthrough in treating diabetes, which they used to treat diabetic foot ulcers. The scaffolds are made using a mixture of hydrogels and lipid nanoparticles. These combine to generate an individually patient-adapted structure that resembles a scaffold and skin. The scaffolds allow for the tailored therapy of diabetic ulcers by continuously releasing molecules laden with antibiotics. Because the "scaffolds" may be produced in any hospital, this therapeutic procedure is not only appealing due to its effectiveness but also because it is sustainable and economical. The 3D-printed dressings also aid medical professionals. Not having to put in and take away the dressing all the time saves much time and effort.

Key Companies in the diabetic ulcer treatment market include

• 
  

  Smith & Nephew PLC (UK)

  
  


• 
  

  Integra LifeSciences Corporation (US)

  
  


• 
  

  SANUWAVE Health

  
  


• 
  

  Cardinal Health (US)

  
  


• 
  

  3M (US)

  
  


• 
  

  Braun Melsungen AG (Germany)

  
  


• 
  

  ACELITY L.P. INC. (US)

  
  

Diabetic Ulcer Treatment Industry Developments

April 2023: The FDA has given the green light to 3M Health Care's pioneering 3M Veraflo therapy, which uses both 3M Veraflo cleanse choice complete dressing and 3M V.A.C. Veraflo cleanse choice dressing to hydromechanically remove infectious materials, non-viable tissue, and wound debris. This aided the business in expanding the range of treatment kinds it offered and in launching those treatment types onto the market.

October 2022:Theruptor Novo, a line of wound dressings from Healthium Medtech, was introduced to treat chronic wounds, particularly diabetic ulcers. With the aid of this strategy, the business was able to expand the range of cutting-edge wound care solutions it offers and meet the industry's expanding demand.

June 2022:In Hull, UK, Smith & Nephew opened a brand-new R&D and manufacturing center for their advanced wound management division. This tactic assisted the business in advancing its research initiatives and expanding its output.

Diabetic Ulcer Treatment Market Segmentation

Diabetic Ulcer Treatment Treatment Outlook (USD Billion, 2018-2032)

• 
  

  Wound Care Dressings

  
  


• 
  

  Wound Care Devices

  
  


• 
  

  Active Therapies

  
  

Diabetic Ulcer Treatment Type Outlook (USD Billion, 2018-2032)

• 
  

   Foot Ulcer

  
  


• 
  

  Mouth Ulcer

  
  

Diabetic Ulcer Treatment End User Outlook (USD Billion, 2018-2032)

• 
  

  Hospitals and Clinics

  
  


• 
  

  Ambulatory Surgical Centers

  
  


• 
  

  Academic and Research Organization

  
  

Diabetic Ulcer Treatment Regional Outlook (USD Billion, 2018-2032)

• 
  

  North America

  
  

• 
  

  US

  
  


• 
  

  Canada

  
  

• 
  

  Europe

  
  

• 
  

  Germany

  
  


• 
  

  France

  
  


• 
  

  UK

  
  


• 
  

  Italy

  
  


• 
  

  Spain

  
  


• 
  

  Rest of Europe

  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America

    
    
  
  
  
  

Report Scope:

Report Attribute/Metric	Details
Market Size 2022	USD 3.9 Billion
Market Size 2023	USD 4.23 Billion
Market Size 2032	USD 8.12 Billion
Compound Annual Growth Rate (CAGR)	8.5% (2023-2032)
Base Year	2022
Market Forecast Period	2023-2032
Historical Data	2018- 2022
Market Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	Treatment, Type, End-User, and Region
Geographies Covered	North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered	The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled	Smith & Nephew PLC (UK), Integra LifeSciences Corporation (US), SANUWAVE Health, Cardinal Health (US), 3M (US), Braun Melsungen AG (Germany) and ACELITY L.P. INC. (US)
Key Market Opportunities	Growing consumer awareness of treatment options and the prevalence of marketing
Key Market Dynamics	Rising number of diabetes patients is driving the market growth

Frequently Asked Questions (FAQ) :